Literature DB >> 20563897

Synthesis and structural characterization of the peptide epitope of the ovarian cancer biomarker CA125 (MUC16).

Zach T Berman1, Lee J Moore, Kathleen E Knudson, Rebecca J Whelan.   

Abstract

A highly conserved region of 21 amino acids flanked by cysteine residues, contained within a larger repeated domain, has been proposed to be the antibody-binding site in the ovarian cancer biomarker CA125 (MUC16). In this study solid-phase peptide synthesis with Fmoc protection chemistry was used to assemble a 21-mer peptide corresponding to the most frequently occurring antibody binding sequence in CA125. Potentially significant sequence variants were also synthesized. Peptide secondary structure was investigated using Fourier transform infrared spectroscopy, revealing the consensus sequence peptide to be largely unstructured at physiological pH whether the cysteine residues were reduced or were oxidized to form an intramolecular disulfide bond. Substitution of serine for proline at position 8 (P8S) results in β-sheet formation in peptides involved in intramolecular disulfide bonds. This β-sheet structure does not persist in peptides incapable of intramolecular disulfide bonding because of sequence nor in peptides treated with the reducing agent dithiothreitol. In CA125, P8S is predicted to occur in ∼25% of repeat domains, suggesting that this structural motif is a non-negligible contributor to overall structure and function. These findings suggest that future structural characterization efforts of CA125 should be especially mindful of the amino acid sequence and oxidation state of the protein.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20563897     DOI: 10.1007/s13277-010-0062-4

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  23 in total

1.  The CA 125 gene: an extracellular superstructure dominated by repeat sequences.

Authors:  T J O'Brien; J B Beard; L J Underwood; R A Dennis; A D Santin; L York
Journal:  Tumour Biol       Date:  2001 Nov-Dec

Review 2.  Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer.

Authors:  Ajay P Singh; Shantibhusan Senapati; Moorthy P Ponnusamy; Maneesh Jain; Subodh M Lele; John S Davis; Steven Remmenga; Surinder K Batra
Journal:  Lancet Oncol       Date:  2008-11       Impact factor: 41.316

Review 3.  What vibrations tell us about proteins.

Authors:  Andreas Barth; Christian Zscherp
Journal:  Q Rev Biophys       Date:  2002-11       Impact factor: 5.318

4.  Molecular cloning of the CA125 ovarian cancer antigen: identification as a new mucin, MUC16.

Authors:  B W Yin; K O Lloyd
Journal:  J Biol Chem       Date:  2001-05-21       Impact factor: 5.157

5.  Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene.

Authors:  Beatrice W T Yin; Ann Dnistrian; Kenneth O Lloyd
Journal:  Int J Cancer       Date:  2002-04-10       Impact factor: 7.396

6.  Effect of glycosylation on MUC1 humoral immune recognition: NMR studies of MUC1 glycopeptide-antibody interactions.

Authors:  Jeffrey S Grinstead; R Rao Koganty; Mark J Krantz; B Michael Longenecker; A Patricia Campbell
Journal:  Biochemistry       Date:  2002-08-06       Impact factor: 3.162

7.  Biophysical characterization of one-, two-, and three-tandem repeats of human mucin (muc-1) protein core.

Authors:  J D Fontenot; N Tjandra; D Bu; C Ho; R C Montelaro; O J Finn
Journal:  Cancer Res       Date:  1993-11-15       Impact factor: 12.701

8.  Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.

Authors:  Zhen Zhang; Yinhua Yu; Fengji Xu; Andrew Berchuck; Carolien van Haaften-Day; Laura J Havrilesky; Henk W A de Bruijn; Ate G J van der Zee; Robert P Woolas; Ian J Jacobs; Steven Skates; Daniel W Chan; Robert C Bast
Journal:  Gynecol Oncol       Date:  2007-10-24       Impact factor: 5.482

9.  Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.

Authors:  Youjun Chen; Suzanna Clark; Terence Wong; Yongmei Chen; Yvonne Chen; Mark S Dennis; Elizabeth Luis; Fiona Zhong; Sheila Bheddah; Hartmut Koeppen; Alvin Gogineni; Sarajane Ross; Paul Polakis; William Mallet
Journal:  Cancer Res       Date:  2007-05-15       Impact factor: 12.701

10.  DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers.

Authors:  C S M Ferreira; C S Matthews; S Missailidis
Journal:  Tumour Biol       Date:  2006-10-09
View more
  3 in total

1.  Affinity-free enrichment and mass spectrometry analysis of the ovarian cancer biomarker CA125 (MUC16) from patient-derived ascites.

Authors:  Naviya Schuster-Little; Roberta Fritz-Klaus; Mark Etzel; Niharika Patankar; Saahil Javeri; Manish S Patankar; Rebecca J Whelan
Journal:  Analyst       Date:  2021-01-04       Impact factor: 4.616

Review 2.  Deciphering the molecular nature of ovarian cancer biomarker CA125.

Authors:  Florian Weiland; Karina Martin; Martin K Oehler; Peter Hoffmann
Journal:  Int J Mol Sci       Date:  2012-08-22       Impact factor: 6.208

Review 3.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.